SCI时时刷

search
Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma
Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma
Acquired resistance is a significant hindrance to clinical application of lenvatinib in unresectable hepatocellular carcin...
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
C-X-C motif chemokine receptor 2 (CXCR2) has a role in tumor progression, lineage plasticity, and reduction of immune chec...
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer
Part E of the KEYNOTE-011 (NCT01840579) study assessed the safety and antitumor activity of pembrolizumab plus platinum-et...
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis
Nivolumab can cause fatal myocarditis. We aimed to analyze the clinical characteristics of nivolumab-induced myocarditis a...
Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells
Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells
This study aimed to prepare SLC7A5 transporters targeted liposomes of Ribociclib (RB) by stear(o)yl conjugation of Phe, As...
Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage
Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage
In recent years, a number of novel pharmaceutical agents have received approval for the management of acute myeloid leukem...
RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma
RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma
Identifying biomarkers to evaluate the therapeutic effect of immune checkpoint inhibitors (ICIs) is crucial. Regulatory As...
Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis
Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis
Gastritis has recently been reported to be associated with nivolumab, and the clinical characteristics of nivolumab induce...
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma
Indoleamine-2,3-dioxygenase (IDO) helps orchestrate immune suppression and checkpoint inhibitor resistance in hepatocellul...
Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study
Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study
Cholangiocarcinoma (CCA) is a primary malignancy which is often diagnosed when it is advanced and inoperable due to the la...
Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification
Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification
Advances in immune checkpoint inhibitors (ICIs) have enabled more effective treatment for individuals with various types o...
Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis
Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is a rare and fatal adverse reaction to pembrolizumab. The clinical characteristi...
The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines
The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines
Alterations in the DNA damage response play a crucial role in radio- and chemoresistance of neoplastic cells. Activation o...
Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide
Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide
Prostate cancer is the second most frequent cancer diagnosed in men, and accounts for one-fifth of cancer associated death...
Antitumor activity of the new tyrphostin briva against BRAFV600E-mutant colorectal carcinoma cells
Antitumor activity of the new tyrphostin briva against BRAFV600E-mutant colorectal carcinoma cells
Because of a reduced sensitivity of BRAF-mutant colorectal cancers to BRAF inhibitor treatment when compared with BRAF-mut...
Gastrointestinal signet ring cell malignancy: current advancement and future prospects
Gastrointestinal signet ring cell malignancy: current advancement and future prospects
Globally, gastrointestinal cancer is the most widespread neoplastic disease and the primary contributor to cancer-associat...
Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial
Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial
Anlotinib plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC) achieves good eff...
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
This open-label, phase 1/1b study was conducted to evaluate the safety, tolerability, and pharmacokinetics (PK) of fruquin...
Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid
Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid
Bullous pemphigoid (BP) is a serious and rare complication of nivolumab. This study aimed to explore the clinical characte...